La cadena de opciones muestra datos clave de las opciones de acciones de Monte Rosa Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Monte Rosa Therapeutics..

Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa, Cadena de Opciones

Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics Inc

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 15 years by 1.49% on an annualized basis producing an average annual return of 13.09%. Currently, Union Pacific has a market capitalization of $137.94 billion. 
Buying $1000 In UNP: If an investor had bought $1000 of UNP stock 15 years ago, it would be worth $6,214.54 today based on a price of $230.87 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747091712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In Union Pacific 15 Years Ago Would Be Worth Today

Warren Buffett has worn the title of "richest man in the world." He's built one of the most powerful holding companies in history. And he's spent decades casually throwing around billion-dollar deals like most people swipe for lattes.
Yet, in his own words, he doesn't need the money.
In 2021, in a statement titled "Comments by Warren E. Buffett in Conjunction with His Annual Contribution of Berkshire Hathaway Shares to Five Foundations," Buffett wrote:
"Over many decades I have accumulated an almost incomprehensible sum simply by doing what I love to do… Society has a use for my money; I don't."
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<a href="https://www.forbes.com/profile/warren-buffett/">According to Forbes</a>, he's donated roughly $62 billion since 2006—part of his long-standing pledge to give away more than 99% of his wealth. Unlike many billionaires who cling to their fortunes or spend it on jets, islands, or ego projects, Buffett's message has been the same: he doesn't need it, he doesn't want it, and he's more than happy to let society put it to better use.
Buffett has made it clear—again and again—that money holds no personal appeal. In a <a href="https://www.bloomberg.com/news/videos/2016-11-02/warren-buffett-money-has-no-utility-to-me-time-does">2016 interview on "The David Rubenstein Show"</a>, he said, "Money in terms of making trips or owning more houses or having a boat or something — it has no utility to me whatsoever."&nbsp;
This is a man who could buy a skyscraper every time he gets bored—but he lives in the same house he bought in <a href="https://www.benzinga.com/personal-finance/25/02/43612207/warren-buffett-has-lived-in-his-31500-home-for-67-years-and-calls-it-one-of-his-best-investments-but-warned-a-house-can-be-a-nightmare">1958 for $31,500</a> and says no other home would make him happier. He drives a 2014 Cadillac with hail damage. He drinks Cherry Coke like it's water.&nbsp;
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
And while the average millionaire might spend weeks negotiating over a single property, <a href="https://www.benzinga.com/personal-finance/25/03/44464242/warren-buffett-said-i-love-your-business-i-love-you-ill-give-you-4-billion-but-refused-to-cross-an-ocean-to-see-a-business-before-buying-it">Buffett once bought a $4 billion company</a>—Israeli metal giant Iscar—without ever stepping foot inside. Another time, he acquired the <a href="https://www.benzinga.com/markets/25/03/44067982/heres-how-warren-buffett-made-billions-from-an-industry-he-didnt-understand">RV company Forest River after a 20-minute chat</a> with the founder.
Although in 2021—when he made the statement about accumulating "an almost incomprehensible sum"—his plan was to give his fortune to five foundations, that's since changed.&nbsp;
In 2025, Buffett revised his estate plan: the remaining $130 billion will instead be transferred to a charitable trust overseen by his three children—Susan, Howard, and Peter. All decisions about how the money is distributed must be made unanimously, a structure Buffett believes will lead to careful, collaborative giving.
Buffett calls his brand of giving "painless," because he's not giving up anything he personally needs. <a href="https://www.benzinga.com/personal-finance/25/05/45240439/ive-made-no-sacrifice-warren-buffett-has-given-away-60-billion-but-says-giving-time-is-more-admirable-ive-done-little-of-that">"I've made no sacrifice,"</a> he said. And he means it. His joy doesn't come from spending—it comes from doing what he loves: investing, building, buying, and reading company reports for fun.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Warren Buffett Says He Made An 'Incomprehensible Sum' Doing What He Loves — But The Money Means Little: 'Society Has A Use For My Money; I Don't'

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 13.02% on an annualized basis producing an average annual return of 28.31%. Currently, Natera has a market capitalization of $21.48 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $348.60 today based on a price of $157.29 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747090814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTRA

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today

Media network CBS has dominated the prime time ratings for more than a decade and helped boost the financials for Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) and subscribers for the company's<a href="https://www.benzinga.com/topic/streaming"> Paramount+ streaming platform.</a>
With concerns over a pending merger and pressure from President Donald Trump, could TV success offset a declining stock price?
What Happened: Paramount Global has a pending merger with Skydance Media. The merger has faced regulatory pressure and a<a href="https://www.benzinga.com/25/04/44793888/trump-attacks-60-minutes-for-unlawful-and-illegal-behavior-could-president-derail-merger"> fight from Trump</a> to take away CBS's FCC broadcast license over past "60 Minutes" episodes could keep the stock from breaking out.
Paramount's CBS Television segment could be a bright spot and shows no signs of slowing down.
As reported by <a href="https://variety.com/2025/biz/news/cbs-upfront-victory-lap-matlock-cheeks-reisenbach-1236393491/">Variety</a>, CBS chose to release its 2025-26 season schedule ahead of media company upfronts, which is when they show off their lineups and new content to advertisers.
Likely helping CBS's decision were several victory laps taken by George Cheeks and Amy Reisenbach over the network's streak of 17 consecutive years as the most-watched network. CBS also has eight of the top 10 most-watched series on television and 16 of the top 25 based on Nielsen data.
CBS has newer hit shows that include "Tracker" and "Matlock." These hit shows and originals have provided a boost to Paramount+, where CBS programs get around half of the total viewing on the platform, according to the report.
"The bottom line here is, our broadcast hits are becoming instant streaming hits," Cheeks said.
Producer Taylor Sheridan has spawned several hits for CBS, including the "Yellowstone" franchise and has more series in the works for CBS, adding more excitement to the company's lineup of returning programs.
"We made some very strategic scheduling moves that will reinforce the schedule that clinched us our 17 seasons at the most-watched network. This is a lineup that's going to be cohesive and has flow with compatible programming each night and throughout the week, and provides strong launch pads for all of our new series," Reisenbach added.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/05/45201601/trump-wants-movies-made-in-america-again-heres-what-tariffs-on-films-could-mean-for-disney-netflix-stock">Trump Wants &#8216;Movies Made In America Again&#8217;: Here&#8217;s What Tariffs On Films Could Mean For Disney, Netflix Stock</a>
Why It's Important: The success of the television segment and a look ahead at what's to come comes as Trump has put pressure on CBS and "60 Minutes," an item that could delay or end the company's merger hopes with Skydance Media.
"This is a disruptive and challenging time for our industry," Cheeks said at the recent event, choosing not to answer questions outside of CBS programming.
"We have to focus on what we control, which is building an amazing schedule."
With the merger in limbo, shareholders face the decision of sticking things out for the combined company or the realization that a merger not going through could send shares lower and force the company to show valuation from the CBS assets on its own.
Paramount <a href="https://www.benzinga.com/general/entertainment/25/05/45358172/paramounts-super-bowl-boost-and-studio-strength-help-offset-streaming-miss-analyst">reported first-quarter</a> revenue of $7.19 billion, beating Street consensus estimates. The company's television segment had revenue of $4.54 billion, beating estimates, while direct-to-consumer revenue of $2.04 billion came in shy of estimates from analysts.
The company's guidance suggests streaming could face tough comps going forward, putting more pressure on the television segment to continue to perform well and be the top-ranked network for the 19th straight year.
PARA Price Action: Paramount stock closed at $11.95 on Monday versus a 52-week trading range of $9.54 to $13.40. Paramount stock is up 13% year-to-date, with shares down 8% over the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/24/09/40754610/paramount-to-be-controlled-by-worlds-sixth-richest-man-larry-ellison-how-helping-his-son-la">Paramount To Be Controlled By World&#8217;s Sixth-Richest Man Larry Ellison: How Helping His Son Landed A Media Stake</a></li>
</ul>
Photo: Fotos593 via Shutterstock

Entertainment

Politics

Media

PARA

PARAA

CBS Highlights TV Dominance, 17-Year Streak On Top: Can Success Help Offset Trump, Merger Concerns?

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 5 years by 6.69% on an annualized basis producing an average annual return of 21.98%. Currently, Primerica has a market capitalization of $9.04 billion. 
Buying $1000 In PRI: If an investor had bought $1000 of PRI stock 5 years ago, it would be worth $2,700.76 today based on a price of $273.29 for PRI at the time of writing.
<h3>Primerica's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747089912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 48.15 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $6.44 million which missed the analyst consensus estimate of $7.42 million by 13.21 percent. This is a 1.24K percent increase over sales of $481.00 thousand the same period last year.

Earnings

Earnings Misses

SGMO

Sangamo Therapeutics Q1 EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.75 per share, will become exercisable six months from the date of issuance and will expire six years from the date of issuance. All of the securities in the offering are to be sold by Sangamo. The offering is expected to close on or about May 14, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds to Sangamo from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $23.0 million. Sangamo intends to use the net proceeds from the offering for working capital and general corporate purposes.
Cantor is acting as sole book-running manager for the offering.

Offerings

Sangamo Therapeutics Prices $23M Underwritten Offering Of 12.235M Shares Of Common Stock And Pre-Funded Warrants At $0.50 And $0.49 Respectively, Including Accompanying Warrants Exercisable At $0.75

Tandy Leather Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLF#NASDAQ">TLF</a>) reported quarterly earnings of $0.05 per share. This is a 16.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $19.04 million in sales this quarter. This is a 1.24 percent decrease over sales of $19.27 million the same period last year.

UPDATE: Tandy Leather Factory Q1 Adj. EPS $0.05 Down From $0.06 YoY, Sales $19.04M Down From $19.27M YoY

Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) reported quarterly earnings of $2.80 per share which beat the analyst consensus estimate of $1.92 by 45.83 percent. This is a 42.86 percent decrease over earnings of $4.90 per share from the same period last year. The company reported $414.00 million in sales this quarter. This is a 3.24 percent increase over sales of $401.00 million the same period last year.

Earnings Beats

Pampa Energia Q1 EPADS $2.80 Beats $1.92 Estimate, Sales $414.00M Up From $401.00M YoY

Infinity Natural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) reported quarterly losses of $(2.27) per share. The company reported $85.17 million in sales this quarter. This is a 69.57 percent increase over sales of $50.23 million the same period last year.

Morgan Stanley Market Vectors Rupee/USD ETN

Infinity Natural Q1 EPS $(2.27), Sales $85.17M Up From $50.23M YoY

BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) reported quarterly losses of $(0.06) per share. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year.

BYSI

UPDATE: BeyondSpring Q1 EPS $(0.06) Down From $(0.05) YoY

Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) has outperformed the market over the past 20 years by 4.32% on an annualized basis producing an average annual return of 12.57%. Currently, Applied Mat has a market capitalization of $136.70 billion. 
Buying $100 In AMAT: If an investor had bought $100 of AMAT stock 20 years ago, it would be worth $1,053.89 today based on a price of $168.20 for AMAT at the time of writing.
<h3>Applied Mat's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747088112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMAT

$100 Invested In Applied Mat 20 Years Ago Would Be Worth This Much Today

Hertz Global Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) reported financial results for the first quarter after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45362896/hertz-reports-significant-progress-towards-key-milestones-for-first-quarter-2025">of the report</a>.
<ul class="wp-block-list">
<li>Q1 Revenue: $1.81 billion, versus <a href="http://benzinga.com/quote/htz/earnings">estimates</a> of $2 billion</li>
</ul>
<ul class="wp-block-list">
<li>Q1 Adjusted Loss: $1.12, versus estimates of 97 cents</li>
</ul>
Total revenue declined 13% on a year-over-year basis, primarily driven by reduced fleet capacity, which was down 8% year-over-year. The company said its fleet rotation is delivering results, with vehicle depreciation down 45% year-over-year. 
Hertz said it&#8217;s targeting less than $300 of depreciation per unit in the second quarter, with model year 2025 vehicles already achieving this target. The company noted that more than 70% of its core U.S. rental fleet is 12 months old or newer. 
Hertz ended the quarter with $1.2 billion of corporate liquidity and said it remains on track to achieve positive adjusted corporate EBITDA by the third quarter of 2025. 
&#8220;Given macro demand uncertainties, it is intentionally running a tighter fleet year-over-year while capitalizing on the strong residual value environment to accelerate the rotation of its remaining older vehicles,&#8221; the company said in the earnings release.
&#8220;Looking forward, the Company sees both macroeconomic uncertainty and opportunity. The Company has recently seen demand moderate for corporate, government and U.S. inbound segments while forward bookings for Hertz leisure are up year-over-year. The Company intends to remain prudent in its fleet management, entering the summer with a relatively tight fleet, and thereby leveraging rising residual values.&#8221;
Hertz executives will further discuss the quarter on a conference call with investors and analysts at 9 a.m. ET Tuesday morning.
HTZ Price Action:<a href="http://benzinga.com/quote/htz"> Hertz shares</a> were down 3.60% after hours, trading at $6.69 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Hertz shares surged last month after Bill Ackman's&nbsp;Pershing Square Capital Management reported a sizable stake in the company. Despite Monday&#8217;s after-hours decline, the stock is still up approximately 89% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45362510/microvision-stock-tumbles-on-q1-earnings-miss-company-highlights-industrial-revenue-opportunities-targets-defense-tech-military-expansion">MicroVision Stock Tumbles On Q1 Earnings Miss, Company Highlights Industrial Revenue Opportunities, Targets Defense Tech, Military Expansion</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45361467/archer-aviation-reports-smaller-than-expected-loss-in-q1-company-says-uae-launch-remains-on-track-for-2025-shares-surge">Archer Aviation Reports Smaller-Than-Expected Loss In Q1, Company Says UAE Launch Remains &#8216;On Track&#8217; For 2025, Shares Surge</a></li>
</ul>
Photo: ricochet64/Shutterstock.

Movers

Hertz Stock Hits The Brakes Following Q1 Earnings Results: Key Details From The Report

ACHR

Archer Aviation Files For Offering Of Up To $19.25M Of Shares Of Class A Common Stock

LSEAW

Trading Halt: Halt status updated at 6:05:00 PM ET: Quotation Resumption: News and Resumption Times

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and raises the price target from $14 to $15.

Price Target

Analyst Ratings

CRVO

Chardan Capital Maintains Buy on CervoMed, Raises Price Target to $15

AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.08 by 37.5 percent. This is a 72.22 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $57.96 million which beat the analyst consensus estimate of $53.90 million by 7.54 percent. This is a 14.07 percent increase over sales of $50.81 million the same period last year.

ALTI

CORRECTION: AlTi Global Q1 Adj. EPS $0.05 Misses $0.08 Estimate, Sales $57.96M Beat $53.90M Estimate

Canaccord Genuity analyst Joseph Vafi maintains Galaxy Digital Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#TSX">GLXY</a>) with a Buy and maintains C$41 price target.

TSX:GLXY

Canaccord Genuity Maintains Buy on Galaxy Digital Holdings, Maintains C$41 Price Target

<a href="https://www.theinformation.com/articles/google-developing-software-ai-agent-pinterest-like-feature-ahead-o">https://www.theinformation.com/articles/google-developing-software-ai-agent-pinterest-like-feature-ahead-o</a>

General

GOOG

GOOGL

'Google Developing Software AI Agent, Pinterest-Like Feature Ahead of I/O'- The Information

In the preceding three months, 8 analysts have released ratings for Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Kennametal, revealing an average target of $23.38, a high estimate of $27.00, and a low estimate of $20.00. This current average has decreased by 6.48% from the previous average price target of $25.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1747087276_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Kennametal among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Kennametal. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Kennametal compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Kennametal's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Kennametal's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kennametal analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Kennametal: A Closer Look</h2>
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
<h3>Unraveling the Financial Story of Kennametal</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Kennametal displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 0.9%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Kennametal's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.47% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Kennametal's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.56%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Kennametal's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.28%, the company showcases efficient use of assets and strong financial health.
Debt Management: Kennametal's debt-to-equity ratio is below the industry average. With a ratio of 0.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Kennametal Stock

Health Care

Press Releases

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Management

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

Comments

Monte Rosa Therapeutics

Monte Rosa Therapeutics (GLUE) Opciones

Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL